Vasculitis in Systemic Lupus Erythematosus
Vasculitis in Systemic Lupus Erythematosus
复制标题
DOI：
10.1007/s11926-014-0440-9
复制
发表时间：
2014-09-01
影响因子：
5
通讯作者：
Barragan-Garfias, J. A.
中科院分区：
文献类型：
--
作者：
Barile-Fabris, L.;Hernandez-Cabrera, M. F.;Barragan-Garfias, J. A.
系统性红斑狼疮（SLE）是一种复杂的异质性自身免疫性疾病，具有多种临床和血清学表现，可累及任何器官。据报道，SLE中血管炎的患病率在11%至36%之间。由于各种尺寸的血管的炎症累及，存在不同的临床谱。即使皮肤病变，代表小血管受累，是最常见的，中型和大型血管炎可能会出现内脏的影响，危及生命的表现，如肠系膜血管炎，肺出血，或多发性单神经炎，有害的后果。早期识别和适当的治疗至关重要。最近的研究表明，SLE患者的血管炎可能会根据受累器官和受累血管的大小而呈现不同的临床形式。值得注意的是，血管炎的发作并不总是伴随着高疾病活动。最近关于这一主题的文章集中在控制血管疾病的新疗法上，例如生物疗法，如利妥昔单抗和贝利木单抗等。
Systemic lupus erythematosus (SLE) is a complex heterogeneous autoimmune disease with a wide variety of clinical and serological manifestations that may affect any organ. Vasculitis prevalence in SLE is reported to be between 11 % and 36 %. A diverse clinical spectrum, due to inflammatory involvement of vessels of all sizes, is present. Even though cutaneous lesions, representing small vessel involvement, are the most frequent, medium and large vessel vasculitis may present with visceral affection, with life-threatening manifestations such as mesenteric vasculitis, pulmonary hemorrhage, or mononeuritis multiplex, with detrimental consequences. Early recognition and an appropriate treatment are crucial. Recent studies have shown that vasculitis in patients with SLE may present different clinical forms based on the organ involved and the size of the affected vessel. It is noteworthy that the episodes of vasculitis are not always accompanied by high disease activity. Recent articles on this topic have focused on new treatments for the control of vascular disease, such as biological therapies such as Rituximab and Belimumab, among others.